Abstract:Antibody drug conjugates (ADCs) are monoclonal antibodies designed to deliver a cytotoxic drug selectively to antigen expressing cells. Several components of an ADC including the selection of the antibody, the linker, the cytotoxic drug payload and the site of attachment used to attach the drug to the antibody are critical to the activity and development of the ADC. The cytotoxic drugs or payloads used to make ADCs are typically conjugated to the antibody through cysteine or lysine residues. This results in ADCs that have a heterogeneous number of drugs per antibody. The number of drugs per antibody commonly referred to as the drug to antibody ratio (DAR), can vary between 0 and 8 drugs for a IgG1 antibody. Antibodies with 0 drugs are ineffective and compete with the ADC for binding to the antigen expressing cells. Antibodies with 8 drugs per antibody have reduced in vivo stability, which may contribute to non target related toxicities. In these studies we incorporated a non-natural amino acid, para acetyl phenylalanine, at two unique sites within an antibody against Her2/neu. We covalently attached a cytotoxic drug to these sites to form an ADC which contains two drugs per antibody. We report the results from the first direct preclinical comparison of a site specific non-natural amino acid anti-Her2 ADC and a cysteine conjugated anti-Her2 ADC. We report that the site specific non-natural amino acid anti-Her2 ADCs have superior in vitro serum stability and preclinical toxicology profile in rats as compared to the cysteine conjugated anti-Her2 ADCs. We also demonstrate that the site specific non-natural amino acid anti-Her2 ADCs maintain their in vitro potency and in vivo efficacy against Her2 expressing human tumor cell lines. Our data suggests that site specific non-natural amino acid ADCs may have a superior therapeutic window than cysteine conjugated ADCs.

Cysteine-Based Coupling: Challenges and Solutions

Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability

Bridged Cysteine Conjugations

Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability

A combination of multiple LC-MS approaches for the comprehensive characterization of cysteine-linked ADCs

In-Depth Structure and Function Characterization of Heterogeneous Interchain Cysteine-Conjugated Antibody-Drug Conjugates

Impact of Drug Conjugation and Loading on Target Antigen Binding and Cytotoxicity in Cysteine Antibody-Drug Conjugates

Antibody-drug conjugates: recent advances in conjugation and linker chemistries

Selective Reduction of Cysteine Mutant Antibodies for Site-Specific Antibody-Drug Conjugates

Emerging conjugation strategies and protein engineering technologies aim to improve ADCs in the fight against cancer

Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry

A Genetically Encoded Photocaged Cysteine for Facile Site-Specific Introduction of Conjugation-Ready Thiol Residues in Antibodies

Nickel-Catalyzed Antibody Bioconjugation

Advances and Limitations of Antibody Drug Conjugates for Cancer

The Evolution of Antibody‐Drug Conjugates: Toward Accurate DAR and Multi‐specificity

Strategies and challenges for the next generation of antibody–drug conjugates

In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates

Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development

Antibody-drug conjugates: Principles and opportunities

Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody–drug conjugates

Lysosomal-Cleavable Peptide Linkers in Antibody–Drug Conjugates